AVD-104 was well-tolerated in all patients, with no drug-related ocular or systemic serious adverse events detected. Substantial slowing of GA lesion growth was observed, and a majority of study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback